Splenic marginal zone lymphoma is a rare form of blood cancer that develops slowly in the spleen, often without immediate symptoms. Treatment decisions depend on how the disease affects each patient, ranging from careful monitoring to combinations of modern medicines that target cancer cells while preserving quality of life.

Understanding Treatment Goals for Splenic Marginal Zone Lymphoma

When someone receives a diagnosis of splenic marginal zone lymphoma, the first question that often comes to mind is about treatment. This rare type of non-Hodgkin lymphoma (a group of cancers affecting the lymphatic system) requires a personalized approach because it behaves differently in each person. The main goals of treatment focus on managing symptoms, slowing the disease’s progression, and maintaining a good quality of life rather than rushing into aggressive therapy.^[1]

Unlike many cancers, splenic marginal zone lymphoma typically grows very slowly. This indolent (slow-growing) nature means that not everyone needs treatment right away. About one in four people with this condition have no symptoms at diagnosis, especially in early stages.^[4] The treatment landscape includes both standard therapies that have been used successfully for years and new approaches being tested in clinical trials around the world. Medical societies and expert groups have developed guidelines to help doctors choose the best approach for each patient based on factors like disease stage, symptoms, and overall health.

Because splenic marginal zone lymphoma predominantly affects the spleen (an organ that filters blood and fights infections), many treatment decisions revolve around this involvement. The disease can also spread to bone marrow, blood, and occasionally lymph nodes near the spleen. Understanding that this lymphoma develops from B cells (a type of white blood cell) in the marginal zone of the spleen helps explain why treatments target these specific cells.^[6]

Treatment choices also consider that this lymphoma is linked to certain infections, particularly hepatitis C virus in about 20 percent of cases. When present, treating the underlying infection sometimes reduces lymphoma symptoms significantly, occasionally eliminating the need for additional cancer treatment.^[7]

Standard Treatment Approaches

Watchful Waiting: Active Surveillance

One of the most common initial approaches is called watchful waiting or active surveillance. This strategy involves carefully monitoring the disease without immediately starting treatment. It’s particularly suitable for people without symptoms or those whose disease is developing very slowly. During watchful waiting, doctors regularly check blood counts, examine the spleen size, and monitor overall health through physical examinations and blood tests.^[7]

This approach recognizes that treatment itself carries risks and side effects, so avoiding therapy until necessary can maintain quality of life. Healthcare teams schedule regular follow-up visits to watch for signs that treatment should begin, such as worsening symptoms, rapidly enlarging spleen, dropping blood counts, or disease spreading to new areas. Many patients remain on watchful waiting for months or even years before needing active treatment.

Treating Underlying Infections

When splenic marginal zone lymphoma is associated with hepatitis C virus infection, doctors first prescribe antiviral drugs before considering cancer-specific treatments. These medications work by eliminating the virus that may be driving lymphoma growth. In some fortunate cases, successful treatment of hepatitis C leads to lymphoma regression, meaning the cancer cells decrease or disappear without additional therapy.^[15]

This connection between infection and lymphoma highlights how chronic inflammation from viruses can trigger abnormal growth of immune cells. By addressing the root cause, antiviral treatment offers a less toxic first step that can sometimes resolve the lymphoma problem entirely.

Targeted Therapy with Rituximab

The most commonly used standard treatment for symptomatic splenic marginal zone lymphoma is rituximab (brand name Rituxan and biosimilar versions). This medication belongs to a class called targeted therapy, which specifically attacks cancer cells while limiting damage to healthy tissue. Rituximab is a monoclonal antibody—a laboratory-made protein that recognizes and binds to a marker called CD20 on the surface of B lymphocytes.^[7]

When rituximab attaches to CD20, it marks the abnormal B cells for destruction by the body’s immune system. The drug is given through intravenous infusion, typically as a series of treatments spread over several weeks. Many patients receive rituximab alone without chemotherapy, especially when the disease is not aggressive. Common side effects during infusion include dizziness, low blood pressure, increased heart rate, numbness, and tingling, but experienced oncology nurses can manage these reactions effectively.^[19]

Rituximab treatment can produce what doctors call a “complete response,” meaning all signs of lymphoma disappear based on imaging scans and blood tests. This state of remission can last for extended periods, sometimes years, before the disease might return.

Chemotherapy Combined with Targeted Therapy

When more intensive treatment is needed, doctors often combine rituximab with chemotherapy drugs. Chemotherapy uses medications that kill rapidly dividing cells, which include cancer cells. The most frequently used combinations for splenic marginal zone lymphoma include:^[7]

• BR (Bendamustine and Rituximab): Bendamustine (brand names Treanda, Benvyon, Esamuze) is a chemotherapy drug that damages cancer cell DNA, preventing them from growing and dividing. When combined with rituximab, this regimen has shown excellent results in treating marginal zone lymphomas.
• R-CHOP: This combination includes rituximab plus four chemotherapy drugs: cyclophosphamide (Procytox), doxorubicin, vincristine, and prednisone (a steroid). It’s a more intensive regimen typically reserved for more active disease.
• R-CVP: Similar to R-CHOP but without doxorubicin, this regimen includes rituximab, cyclophosphamide, vincristine, and prednisone, offering a slightly less intensive option.
• Chlorambucil and Rituximab: Chlorambucil (Leukeran) is an older chemotherapy drug taken as pills rather than intravenous infusion, making it convenient for some patients.

Treatment duration varies depending on the specific regimen chosen. Most chemotherapy courses last several months, with treatments given in cycles—periods of treatment followed by rest periods to allow the body to recover. The rest periods are crucial because they give healthy cells time to repair while cancer cells remain more vulnerable to the next treatment cycle.

Side effects from chemotherapy combinations can include fatigue, increased infection risk due to low white blood cell counts, anemia (low red blood cells causing tiredness), easy bruising or bleeding from low platelets, hair loss (though less common with some regimens), nausea, and mouth sores. Modern supportive care medications can prevent or reduce many of these side effects, and healthcare teams work closely with patients to manage any problems that arise.

Surgical Removal of the Spleen

Surgery to remove the spleen, called splenectomy, was once a primary treatment for splenic marginal zone lymphoma but is now used more selectively. This procedure is considered when the enlarged spleen causes significant discomfort or pressure on other organs, or when it’s destroying too many blood cells (a condition called hypersplenism), leading to dangerous drops in red blood cells, white blood cells, or platelets.^[7]

Splenectomy can effectively control the disease for extended periods and improve blood counts in many patients. However, removing the spleen permanently reduces immune function, particularly the ability to fight certain bacterial infections. After splenectomy, patients need vaccinations against pneumococcus, meningococcus, and Haemophilus influenzae bacteria, and some require lifelong preventive antibiotics.

Because newer drug treatments like rituximab and chemotherapy combinations can be equally effective with less permanent impact on immune function, splenectomy is now typically reserved for specific situations rather than used as first-line therapy.^[4]

Treatment for Relapsed or Refractory Disease

When splenic marginal zone lymphoma returns after initial treatment (relapsed disease) or doesn’t respond to first treatments (refractory disease), additional drug options are available. These include newer targeted therapies such as:^[7]

• Ibrutinib (Imbruvica): This drug blocks a protein called Bruton’s tyrosine kinase (BTK) that helps B cells grow and survive. By inhibiting this protein, ibrutinib can stop lymphoma cells from multiplying.
• Zanubrutinib (Brukinsa): Another BTK inhibitor similar to ibrutinib but designed to be more selective and potentially cause fewer side effects.
• Lenalidomide (Revlimid): This medication works through multiple mechanisms, including modifying immune system activity and preventing cancer cells from forming new blood vessels they need for growth.

These medications are typically taken as daily pills and may be covered differently by various health insurance plans, so patients should discuss coverage and cost considerations with their healthcare teams.

Promising Treatments in Clinical Trials

Research into splenic marginal zone lymphoma continues actively, with clinical trials testing new approaches that may become standard treatments in the future. Clinical trials proceed through phases: Phase I trials test safety and determine appropriate dosing in small groups of patients; Phase II trials evaluate whether treatments work against the disease in larger patient groups; Phase III trials compare new treatments directly against current standard therapies to determine if they’re better or have fewer side effects.

Bendamustine-Rituximab Optimization Studies

Recent clinical trials have focused on optimizing the bendamustine-rituximab combination specifically for splenic marginal zone lymphoma. A significant Phase II study called BRISMA/IELSG36 evaluated this combination as first-line treatment for symptomatic patients. The trial demonstrated excellent long-term outcomes, with many patients achieving complete responses that lasted for years.^[12]

This study also investigated something called minimal residual disease (MRD)—extremely small amounts of cancer cells that remain after treatment but are undetectable by standard tests. Researchers used highly sensitive molecular techniques to measure MRD in blood and bone marrow samples. Patients who achieved unmeasurable MRD early in their treatment course had significantly better long-term outcomes, suggesting that this measurement could help predict which patients will have the best responses.

The findings from this trial have influenced treatment approaches in Europe and are being studied further to determine whether MRD-guided therapy adjustments could improve outcomes. This means potentially intensifying treatment for patients with persistent MRD or de-escalating therapy for those who achieve unmeasurable MRD quickly.

Novel BTK Inhibitors

While ibrutinib and zanubrutinib are now available for relapsed disease, clinical trials continue testing these and newer BTK inhibitors in different settings. Some trials are evaluating whether using BTK inhibitors earlier in the disease course—as first-line treatment rather than waiting for relapse—might improve outcomes. Other studies combine BTK inhibitors with rituximab or other agents to see if combinations work better than single drugs.

These trials typically enroll patients in specialized cancer centers across the United States, Europe, and increasingly in other regions including Brazil and Asia. Eligibility usually requires confirmed diagnosis through biopsy, measurable disease, and adequate organ function. Some trials specifically seek patients who haven’t received prior treatment (first-line studies), while others focus on relapsed or refractory cases.

Immunotherapy Approaches

Beyond rituximab, which is technically a form of immunotherapy, researchers are exploring other ways to harness the immune system against lymphoma. These include:

• Checkpoint inhibitors: Drugs that block proteins that normally prevent the immune system from attacking cells too aggressively. By blocking these “brakes,” checkpoint inhibitors unleash immune cells to attack lymphoma more vigorously.
• Bispecific antibodies: Laboratory-made proteins designed to bind simultaneously to lymphoma cells and immune cells, bringing them together so immune cells can destroy the cancer.
• CAR T-cell therapy: A personalized treatment where doctors collect a patient’s own immune cells, genetically modify them in the laboratory to better recognize and attack lymphoma, then infuse them back into the patient.

While these approaches have shown remarkable success in other types of lymphoma, studies in marginal zone lymphomas including the splenic subtype are still in relatively early phases. These treatments are being evaluated primarily in patients whose disease has relapsed after multiple prior therapies.

Targeting Genetic Abnormalities

Scientists have identified specific genetic changes in splenic marginal zone lymphoma cells. A significant proportion of patients have deletions (missing pieces) of chromosome 7, particularly the region 7q21-32, which occurs in about 40 percent of cases.^[9] Understanding these molecular features is helping researchers develop treatments that target the specific pathways affected by these genetic changes.

Some clinical trials are testing drugs that target pathways controlled by genes in these deleted regions. For example, abnormalities in genes regulating the NF-κB pathway—a critical signaling system inside cells that controls inflammation and cell survival—are common in marginal zone lymphomas. Drugs specifically designed to block overactive NF-κB signaling are being evaluated in early-phase trials.

Venetoclax in Combination Regimens

Venetoclax is a drug that blocks a protein called BCL-2, which helps cancer cells avoid normal cell death. By inhibiting BCL-2, venetoclax essentially removes the “survival signal” that keeps lymphoma cells alive. While venetoclax is approved for other B-cell cancers like chronic lymphocytic leukemia, clinical trials are testing whether it works in marginal zone lymphomas, often in combination with rituximab or BTK inhibitors.

Early results from Phase I and Phase II trials suggest that venetoclax combinations may be effective, with some patients achieving responses. These studies carefully monitor for side effects, particularly a condition called tumor lysis syndrome, where rapid destruction of cancer cells releases their contents into the bloodstream faster than the body can clear them, potentially causing kidney problems and electrolyte imbalances.

Improved Diagnostic Tools and Treatment Selection

An important area of clinical research involves developing better ways to determine which treatments will work best for individual patients. This includes studies using advanced genetic sequencing to identify all the mutations present in each patient’s lymphoma cells, then matching treatments to target those specific abnormalities—an approach called precision medicine.

Trials are also evaluating new imaging techniques beyond standard CT and PET scans, including novel radioactive tracers that specifically bind to lymphoma cells, making them easier to detect and monitor. Better imaging could help doctors determine earlier whether treatment is working, allowing adjustments before unnecessary side effects accumulate.

Most Common Treatment Methods

• Watchful Waiting (Active Surveillance)
  • Careful monitoring without immediate treatment for patients without symptoms or slowly progressing disease
  • Regular physical examinations, blood tests, and imaging to detect when treatment becomes necessary
  • Allows maintaining quality of life by avoiding treatment side effects until therapy is needed
• Antiviral Therapy
  • Treatment of hepatitis C virus infection with antiviral medications before starting lymphoma-specific therapy
  • Can sometimes lead to lymphoma regression without additional cancer treatment
  • Addresses the underlying infection that may be driving lymphoma growth
• Targeted Therapy
  • Rituximab (Rituxan and biosimilars) as monotherapy or combined with chemotherapy
  • Works by targeting CD20 protein on B lymphocytes, marking cancer cells for immune destruction
  • BTK inhibitors (ibrutinib, zanubrutinib) for relapsed or refractory disease
  • Lenalidomide for patients whose disease returns after initial treatment
• Chemotherapy
  • Bendamustine combined with rituximab (BR regimen) is a frequently used combination
  • R-CHOP combination for more active disease requiring intensive treatment
  • R-CVP regimen offering slightly less intensive option than R-CHOP
  • Chlorambucil with rituximab for patients preferring oral medication
  • Cyclophosphamide combined with rituximab as another option
• Surgery
  • Splenectomy (surgical removal of the spleen) for symptom relief when the enlarged spleen causes discomfort
  • Improves blood cell counts when the spleen is destroying too many cells
  • Now used more selectively since drug treatments can be equally effective
  • Requires lifelong vaccinations and sometimes preventive antibiotics after surgery